FY2025 EPS Estimates for Genmab A/S Lifted by HC Wainwright

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Equities research analysts at HC Wainwright raised their FY2025 earnings estimates for shares of Genmab A/S in a report issued on Wednesday, January 28th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of $2.00 for the year, up from their prior estimate of $1.89. HC Wainwright currently has a “Buy” rating and a $39.00 price target on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share. HC Wainwright also issued estimates for Genmab A/S’s Q1 2026 earnings at $0.27 EPS, Q2 2026 earnings at $0.49 EPS and Q3 2026 earnings at $0.47 EPS.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.65 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.17. The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $975.40 million. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%.

A number of other brokerages have also issued reports on GMAB. Truist Financial reiterated a “buy” rating and set a $48.00 price target (down from $49.00) on shares of Genmab A/S in a research note on Thursday, November 6th. Weiss Ratings restated a “hold (c)” rating on shares of Genmab A/S in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Genmab A/S from a “hold” rating to a “buy” rating in a report on Saturday, November 22nd. Zacks Research cut shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 31st. Finally, Johnson Rice restated a “buy” rating on shares of Genmab A/S in a research note on Monday, October 27th. Six equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $39.25.

Genmab A/S Trading Down 2.2%

GMAB opened at $32.63 on Thursday. The stock’s 50-day moving average price is $32.47 and its 200 day moving average price is $29.05. Genmab A/S has a 12-month low of $17.24 and a 12-month high of $35.43. The firm has a market cap of $20.96 billion, a price-to-earnings ratio of 13.89, a PEG ratio of 19.53 and a beta of 0.90.

Institutional Investors Weigh In On Genmab A/S

Several institutional investors have recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Genmab A/S during the second quarter worth $257,000. Park Avenue Securities LLC lifted its holdings in Genmab A/S by 5.9% during the 2nd quarter. Park Avenue Securities LLC now owns 14,940 shares of the company’s stock worth $309,000 after buying an additional 832 shares during the last quarter. DAVENPORT & Co LLC boosted its position in shares of Genmab A/S by 6.8% during the 2nd quarter. DAVENPORT & Co LLC now owns 33,826 shares of the company’s stock worth $699,000 after acquiring an additional 2,147 shares in the last quarter. Callan Family Office LLC purchased a new position in shares of Genmab A/S in the 2nd quarter valued at about $655,000. Finally, Blue Trust Inc. increased its holdings in shares of Genmab A/S by 33.2% in the 2nd quarter. Blue Trust Inc. now owns 9,871 shares of the company’s stock valued at $204,000 after acquiring an additional 2,458 shares during the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Genmab A/S

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating and $39 target while raising FY2025 estimates (now $2.00 EPS) and some near‑term quarter forecasts, providing support under the stock. HC Wainwright Reiterates “Buy” Rating for Genmab A/S (NASDAQ:GMAB)
• Neutral Sentiment: Genmab disclosed grants of 32,806 restricted stock units and 34,307 warrants to employees — normal for biotech compensation but potentially modestly dilutive if exercised; not likely to be a major near‑term earnings driver. Grant of Restricted Stock Units and Warrants to Employees in Genmab
• Neutral Sentiment: Reported short‑interest data for January appears to show no meaningful or reliable change (entries show zero/NaN), so short covering is not a clear factor in today’s move.
• Negative Sentiment: HC Wainwright cut multiple 2026 quarterly and full‑year EPS forecasts: FY2026 now $1.68 (was $2.14); Q4 2026 to $0.46 (from $0.63); Q1 2026 to $0.27 (from $0.34); Q2 2026 to $0.49 (from $0.58); Q3 2026 to $0.47 (from $0.59). Those downgrades lower near‑term earnings visibility and are the primary reason investors are marking the stock down today.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.